Inovio Pharmaceuticals (NYSE:INO) CEO Jong Joseph Kim purchased 25,000 shares of the stock in a transaction dated Tuesday, April 15th. The stock was purchased at an average cost of $2.25 per share, for a total transaction of $56,250.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,965,809 shares in the company, valued at approximately $13,423,070. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) shares after opening at $2.63 moved to $2.72 on last trade day and at the end of the day closed at $2.52. Company price to sales ratio in past twelve months was calculated as 44.83 and price to cash ratio as 11.51. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) showed a negative weekly performance of -16.00%.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Director Bruce Kovner bought 1,250,000 shares of Synta Pharmaceuticals Corp. stock on the open market in a transaction dated Friday, April 11th. The shares were purchased at an average price of $4.01 per share, for a total transaction of $5,012,500.00. Following the acquisition, the director now directly owns 3,048,666 shares in the company, valued at approximately $12,225,151. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) shares fell -1.73% in last trading session and ended the day on $3.97. SNTA return on equity ratio is recorded as -231.70% and its return on assets is -112.90%. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) yearly performance is -58.03%.
Oramed Pharmaceuticals (NASDAQ:ORMP) major shareholder Regals Capital Management Lp bought 75,000 shares of the company’s stock on the open market in a transaction that occurred on Tuesday, March 25th. The stock was purchased at an average price of $10.62 per share, with a total value of $796,500.00. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) shares moved down -2.95% in last trading session and was closed at $12.17, while trading in range of $11.99 – $12.80. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) year to date (YTD) performance is -21.13%.
Repligen Corporation (NASDAQ:RGEN)’s SVP Daniel P Witt buy 10,000 shares of RGEN in a transaction dated on April 15, 2014. Repligen Corporation (NASDAQ:RGEN) shares were bought at an average price of $3.05 for total worth of $30,500.00.Repligen Corporation (NASDAQ:RGEN) weekly performance is 15.79%. On last trading day company shares ended up $15.84. Repligen Corporation (NASDAQ:RGEN) distance from 50-day simple moving average (SMA50) is 8.37%. Analysts mean target price for the company is $16.50.
Leave a Reply